摘要
目的评价阿奇霉素治疗支气管哮喘的临床疗效,对肺功能和细胞因子的影响及其治疗安全性。方法本实验40例哮喘患者,随机分入阿奇霉素联合吸入性糖皮质激素加长效β2-肾上腺素受体激动剂组,或吸入性糖皮质激素加长效2β-肾上腺素受体激动剂组,评估治疗前后各组患者哮喘控制测试评分、肺功能、诱导痰标本内细胞因子IL-4I、L-5和IFN-γ的浓度变化,及阿奇霉素的不良反应。结果治疗12周后,两组患者的哮喘控制测试评分、肺功能指标较治疗前均明显改善,诱导痰细胞因子的浓度亦明显下降,差异有统计学意义;阿奇霉素组诱导痰标本内细胞因子浓度较对照组下降明显,差异有统计学意义;两组均未出现严重的不良事件。结论阿奇霉素联合吸入性糖皮质激素加长效β2-肾上腺素受体激动剂治疗哮喘安全有效,可有效降低哮喘患者气道内Th2细胞因子含量。
Objective To evaluate the clinical efficacy, impacts on lung function and cytokines, and safety of azithromycin on the treatment for asthma. Methods Forty patients with asthma were randomized equally to receive azithromycin combined with inhaled cortisteroid （ICS） plus long-acting β2-agonists （LABA）, or only ICS plus LABA for 12 weeks. We evaluated the clinical efficacy including asthma control test scores and lung function, cytokines in induced-sputum including interleukin-4, interleukin-5 and interferon-γ, and the safety of azithromycin. Results After 12 weeks, asthma control test （ACT） scores and lung function were improved obviously, and concentrations of IL-4, IL-5 and IFN-γ in induced-sputum were reduced significantly in both groups. Comparing with the control group, the decline of cytokines in induced-sputum was much more significant in patients treated with azithromycin. No severe adverse events were found in both groups. Conclusions Azithromycin combined with ICS plus LABA is an effective and safe treatment for asthma, which could significantly reduce the level of cytokines elaborated from Th2-type cells in the airways.
出处
《复旦学报（医学版）》
CAS
CSCD
北大核心
2009年第6期719-722,共4页
Fudan University Journal of Medical Sciences
关键词
哮喘
阿奇霉素
诱导痰
细胞因子
asthma
azithromycin
induced sputum
cytokines
